Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy
On Friday, Editas offered a preliminary update on the handful of patients who’ve received its gene-editing-based therapy for sickle cell, which is also being tested for another blood disorder, beta thalassemia.